Department of Psychiatry, Severance Hospital
Seoul, 120-752, South Korea
NCT Number: NCT01325831
In order to explore the effect of repetitive TMS, which has shown to be effective in intractable depression, we will examine resting-state, default-mode network functional connectivity in patients with major depression. We will use a double-blind, sham-controlled design. Our target sample size is 60(30 patients will be treated by active rTMS, the other 30 will be treated by sham rTMS). We will apply 10-day course of 10 Hz rTMS on left dorsolateral prefrontal cortex of the subjects.
Looking for future studies?
Notify Me19 year–70 year
All sexes
Interventional
Phase 4
Seoul, 120-752, South Korea
Up to now, 24 patients with major depression and 6 normal controls are enrolled. Twenty-three patients and 4 normal participants have taken 10 days rTMS. One patients and one control withdrew their consent without any reason and one control withdrew the consent because of headache.
We scanned fMRIs(to examine functional connectivity)twice for each participant, which were taken 3 days before the first and 3 days after the last rTMS.
All of participants have not reported side effects except mild headahe. There's been no seizure event up to now.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
10-day course of 10 Hz rTMS on left dorsolateral prefrontal cortex of the subjects.
Other names: MAGSTIM
Sham repetitive transcranial magnetic stimulation(rTMS)
Time frame: 14 days
Yonsei University
Other
Change of Dopamine Pathway After rTMS Treatment in Major Depressive Disorder
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05497414
Depressive Disorder, Depressive Disorder, Major
Boston, Massachusetts, United States
View Trial DetailsNCT05257902
Depressive Disorder, Depressive Disorder, Major
Seoul, Irwon-dong, Gangnam-gu, South Korea
View Trial DetailsNCT01962753
Depressive Disorder, Depressive Disorder, Major
Besançon, France
View Trial DetailsNCT06748274
Autonomous Dysfunction, Behavior
Bern, Canton of Bern, Switzerland
View Trial Details